|
AU687117B2
(en)
*
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US20060275261A1
(en)
*
|
1993-10-25 |
2006-12-07 |
Canji, Inc. |
Adenoviral vectors having a protein IX deletion
|
|
US6210939B1
(en)
|
1993-10-25 |
2001-04-03 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US20010006629A1
(en)
*
|
1993-10-25 |
2001-07-05 |
Richard J. Gregory |
Recombinant adenoviral vector and methods of use
|
|
US7001733B1
(en)
|
1998-05-12 |
2006-02-21 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
|
|
US7060433B1
(en)
|
1999-11-12 |
2006-06-13 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions for screening using diphtheria toxin constructs
|
|
DE19845434C1
(de)
*
|
1998-10-02 |
2000-03-16 |
Juergen Schrader |
Gewebebindende Peptide, ihre Identifizierung, Herstellung und Verwendung
|
|
ATE483816T1
(de)
*
|
1998-11-19 |
2010-10-15 |
Univ Georgetown |
Systemisches virus/ligand genabgabemittel und gentherapie
|
|
AU5011200A
(en)
|
1999-05-14 |
2000-12-05 |
Arbor Vita Corporation |
Molecular interactions in hematopoietic cells
|
|
EP1223952B1
(en)
*
|
1999-10-07 |
2008-04-16 |
Carlos Estuardo Aguilar-Cordova |
Methods for treatment of solid tumors and metastasis by gene therapy
|
|
AU1194501A
(en)
*
|
1999-10-14 |
2001-04-23 |
Wistar Institute, The |
Inhibition of tumorigenic properties of melanoma cells
|
|
AU2001234981A1
(en)
*
|
2000-02-09 |
2001-08-20 |
Genvec, Inc. |
Adenoviral capsid containing chimeric protein ix
|
|
AU2001237256A1
(en)
*
|
2000-03-08 |
2001-09-17 |
Neurosearch A/S |
A method of sensitising endothelial cells to prodrugs
|
|
IL153853A0
(en)
*
|
2000-07-10 |
2003-07-31 |
Novartis Ag |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
|
US6506365B1
(en)
*
|
2000-09-25 |
2003-01-14 |
Baxter Aktiengesellschaft |
Fibrin/fibrinogen binding conjugate
|
|
US7306792B2
(en)
*
|
2001-03-27 |
2007-12-11 |
New York University |
Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
|
|
DE60234100D1
(de)
*
|
2001-04-24 |
2009-12-03 |
Vlaams Interuniv Inst Biotech |
Verwendung von "hypoxia inducible factor 2alpha" zur behandlung von "neonatal respiratory distress syndrome"
|
|
JP2002335965A
(ja)
*
|
2001-05-14 |
2002-11-26 |
Japan Science & Technology Corp |
細胞特異的発現複製ベクター
|
|
US7226587B2
(en)
|
2001-06-01 |
2007-06-05 |
Wyeth |
Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
|
|
WO2002103004A1
(en)
*
|
2001-06-15 |
2002-12-27 |
The Children's Hospital Of Philadelphia |
Surface modification for improving biocompatibility
|
|
KR100996226B1
(ko)
*
|
2001-10-31 |
2010-11-24 |
유니버시티 오브 노스 텍사스 헬스 사이언스 센터 |
뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
|
|
US20030133912A1
(en)
*
|
2001-12-11 |
2003-07-17 |
Davidson Beverly L. |
Receptor-targeted adenoviral vectors
|
|
FR2842823A1
(fr)
*
|
2002-07-25 |
2004-01-30 |
Inst Nat Sante Rech Med |
Adenovirus modifies pour le ciblage des lymphocytes b
|
|
US7033333B1
(en)
*
|
2002-08-02 |
2006-04-25 |
Arthur Croft |
Self actuated cervical (neck) traction device
|
|
WO2004029581A2
(en)
*
|
2002-09-26 |
2004-04-08 |
The Children's Hospital Of Philadelphia |
Method of determining surface binding capacity
|
|
CN1327899C
(zh)
*
|
2003-05-10 |
2007-07-25 |
彭朝晖 |
腺病毒载体与p53基因的基因重组体的应用
|
|
US20070098702A1
(en)
*
|
2005-02-17 |
2007-05-03 |
University Of Maryland, Baltimore |
Recombinant protein polymer vectors for systemic gene delivery
|
|
WO2007050128A2
(en)
*
|
2005-05-31 |
2007-05-03 |
Vectorlogics, Inc. |
Shielded adenoviral vectors and methods of use
|
|
WO2006130690A2
(en)
*
|
2005-06-01 |
2006-12-07 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
|
US7858356B2
(en)
|
2005-11-24 |
2010-12-28 |
Genomidea, Inc. |
Mutant paramyxovirus and method for production thereof
|
|
US7659999B2
(en)
*
|
2005-12-23 |
2010-02-09 |
Xerox Corporation |
UIdesign: N-up calculator user interface
|
|
CA2637600A1
(en)
|
2006-01-17 |
2007-07-26 |
Health Research, Inc. |
Heteroduplex tracking assay
|
|
WO2008128251A1
(en)
|
2007-04-17 |
2008-10-23 |
The Children's Hospital Of Philadelphia |
Humanized viral vectors and methods of use thereof
|
|
WO2009137689A2
(en)
*
|
2008-05-07 |
2009-11-12 |
Surmodics, Inc. |
Delivery of nucleic acid complexes from particles
|
|
US20110159098A1
(en)
*
|
2009-12-30 |
2011-06-30 |
Surmodics, Inc. |
Stabilization and delivery of nucleic acid complexes
|
|
US8389804B2
(en)
|
2010-04-08 |
2013-03-05 |
University Of Florida Research Foundation, Inc. |
Viral based transient-expression vector system that allows multiple applications
|
|
CN102933713B
(zh)
*
|
2010-04-08 |
2015-05-13 |
佛罗里达大学研究基金会有限公司 |
具有多功能的瞬时表达病毒载体体系
|
|
US8901092B2
(en)
|
2010-12-29 |
2014-12-02 |
Surmodics, Inc. |
Functionalized polysaccharides for active agent delivery
|
|
RU2542385C2
(ru)
*
|
2012-08-31 |
2015-02-20 |
Общество с ограниченной ответственностью "НекстГен" |
Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
|
|
US10947282B2
(en)
|
2015-01-19 |
2021-03-16 |
The Texas A & M University System |
Functionalized protein-based materials and their uses
|
|
RU2612497C2
(ru)
|
2015-05-26 |
2017-03-09 |
Общество с ограниченной ответственностью "НекстГен" |
Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
|
|
EP3625714B1
(en)
|
2017-05-16 |
2021-03-17 |
Life Technologies Corporation |
Methods for compression of molecular tagged nucleic acid sequence data
|
|
US20220340627A1
(en)
*
|
2019-09-20 |
2022-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Dach1 builds artery networks that protect against cardiac injury in adults
|